(FM) Oncología
Departamento académico
Copenhagen University Hospital
Copenhague, DinamarcaPublicaciones en colaboración con investigadores/as de Copenhagen University Hospital (31)
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions
International Journal of Gynecological Cancer, Vol. 33, Núm. 11, pp. 1733-1742
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
-
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Cancer, Vol. 129, Núm. 12, pp. 1846-1855
-
Safety and management of niraparib monotherapy in ovarian cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981
2022
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Annals of Oncology, Vol. 33, Núm. 3, pp. 276-287
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context
Future Oncology, Vol. 18, Núm. 23, pp. 2505-2536
2021
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
-
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
The Lancet. Oncology, Vol. 22, Núm. 5, pp. 609-619
2020
-
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners -a new Model D for drug and medical device development
International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 730-734
-
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey